Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB-102 in Bipolar I Disorder Major Depressive Episodes
NCT07494305Phase 2Recruiting
- Sponsor
- LB Pharmaceuticals
- Start
- Jan 2026
- Primary completion
- Feb 2028
- Modality
- T-cell Engagers, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LP-102 in bipolar I disorder, sponsored by LB Pharmaceuticals. Started Jan 2026; status: recruiting.
02
Drugs
LP-102
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT07494305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07494305.